Analysts Anticipate Tetraphase Pharmaceuticals Inc (TTPH) Will Post Earnings of -$0.34 Per Share

Brokerages expect Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to announce earnings of ($0.34) per share for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Tetraphase Pharmaceuticals’ earnings. The highest EPS estimate is ($0.26) and the lowest is ($0.40). Tetraphase Pharmaceuticals reported earnings of ($0.63) per share in the same quarter last year, which would suggest a positive year over year growth rate of 46%. The firm is expected to announce its next quarterly earnings report on Thursday, November 1st.

According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year earnings of ($1.39) per share for the current fiscal year, with EPS estimates ranging from ($1.82) to ($1.03). For the next fiscal year, analysts forecast that the company will report earnings of ($1.18) per share, with EPS estimates ranging from ($1.77) to ($0.81). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.18. Tetraphase Pharmaceuticals had a negative net margin of 421.64% and a negative return on equity of 67.34%. The business had revenue of $11.58 million during the quarter, compared to analysts’ expectations of $2.23 million.

A number of equities analysts recently weighed in on TTPH shares. Zacks Investment Research cut shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Friday, August 3rd. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, July 30th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Tetraphase Pharmaceuticals in a research report on Monday, July 16th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the stock. Tetraphase Pharmaceuticals has an average rating of “Hold” and a consensus price target of $6.66.

Large investors have recently bought and sold shares of the stock. Deutsche Bank AG boosted its position in Tetraphase Pharmaceuticals by 168.6% in the 4th quarter. Deutsche Bank AG now owns 221,425 shares of the biopharmaceutical company’s stock valued at $1,394,000 after buying an additional 138,996 shares during the period. BlackRock Inc. boosted its position in Tetraphase Pharmaceuticals by 21.2% in the 4th quarter. BlackRock Inc. now owns 4,044,340 shares of the biopharmaceutical company’s stock valued at $25,479,000 after buying an additional 707,296 shares during the period. Two Sigma Investments LP boosted its position in Tetraphase Pharmaceuticals by 276.7% in the 4th quarter. Two Sigma Investments LP now owns 64,413 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 47,313 shares during the period. Alambic Investment Management L.P. purchased a new position in Tetraphase Pharmaceuticals in the 1st quarter valued at approximately $356,000. Finally, Renaissance Technologies LLC boosted its position in Tetraphase Pharmaceuticals by 77.6% in the 4th quarter. Renaissance Technologies LLC now owns 592,493 shares of the biopharmaceutical company’s stock valued at $3,733,000 after buying an additional 258,908 shares during the period. 43.32% of the stock is owned by hedge funds and other institutional investors.

Shares of Tetraphase Pharmaceuticals stock traded down $0.14 during mid-day trading on Friday, hitting $2.95. The stock had a trading volume of 942,788 shares, compared to its average volume of 1,051,855. Tetraphase Pharmaceuticals has a 12-month low of $2.05 and a 12-month high of $7.98. The stock has a market cap of $170.21 million, a price-to-earnings ratio of -1.12 and a beta of 2.44.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

See Also: Average Daily Trade Volume – What You Need to Know

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply